OpenEvidence Logs 30 Million Doctor Consultations, Reaching $12 Billion Valuation
Updated
Updated · The New York Times · Jun 8
OpenEvidence Logs 30 Million Doctor Consultations, Reaching $12 Billion Valuation
2 articles · Updated · The New York Times · Jun 8
Summary
30 million physician questions and consultations ran through OpenEvidence last month, nearly double the volume six months earlier, underscoring how quickly the medical AI app has spread.
More than half of U.S. physicians are now regular users, according to the startup, using the tool to answer specific medical questions and test diagnostic ideas during patient care.
Mount Sinai found about one-third of its 9,000 doctors were already regular users, a sign that adoption had moved well beyond isolated early adopters.
A separate 2025 survey of 1,000 physicians found 45% used OpenEvidence—nearly triple ChatGPT's share among doctors—helping drive the company's valuation to $12 billion in January from $3.5 billion last July.
As half of US doctors embrace an AI assistant, are we trading irreplaceable human expertise for algorithmic efficiency?
Your doctor's new partner is a 'black box' AI. What happens when its life-or-death advice is wrong?
OpenEvidence’s $12 Billion Surge: How “ChatGPT for Doctors” Is Transforming Medical AI and Clinical Decision-Making
Overview
OpenEvidence, launched in 2022 by Daniel Nadler and Zachary Ziegler, has quickly become a leading force in medical AI by focusing on helping doctors make critical decisions. Unlike other tools, it trains its AI models only on data from top scientific journals, ensuring high-quality and reliable information. Formal partnerships with respected organizations like the New England Journal of Medicine and the American Medical Association further strengthen its trustworthiness. This strong foundation has led to rapid adoption among physicians, making OpenEvidence a go-to resource for clinical decision support and setting a new standard in healthcare technology.